Industry news

Study Looks at Diagnostic Utility of Clinical Whole-Genome Sequencing

GenomeWeb

Whole-genome sequencing continues to show promise for diagnosing genetic disorders in the clinic, according to a new analysis in Nature Genetics, which sifted through factors involved in reliably narrowing in on authentic disease-causing variants from genome sequences for individuals with Mendelian or immunological conditions.

ICYMI: New Oncology Trend Report Highlights the Future Promise of Innovation

PhRMA

As part of our Healthy Outlook: Conquering Cancer in the 21st Century blog series, we wanted to highlight a new report from IMS Institute for Healthcare Informatics that examines the global market for oncology treatment. According to the report, cancer care is evolving and improving as new therapies emerge and innovation continues, underscoring the importantance of a competitive biopharmaceutical marketplace to control costs and push biopharmaceutical manufacturers to innovate. 

Want to know a secret? Pharma's patient services are going to waste

Beth Snyder Bulik / FiercePharmaMarketing

Patient services are apparently one of pharma's best kept secrets, according to a study out today from Accenture. Fewer than one-fifth (19%) of patients surveyed knew about available patient services, such as prescription assistance, support groups, nurse visits, referrals and financial assistance.

Advice for med tech entrepreneurs: Identify your customer and consider stakeholders' incentives carefully

Varun Saxena / FierceMedicalDevices

The med tech ecosystem is diverse and teeming with myriad stakeholders, to the point that identifying the customer of a company or device can be challenging.

The top 10 advertisers in Big Pharma

Beth Snyder Bulik / FiercePharmaMarketing

While the list of the top spending DTC ad spenders changes every year, there are always a few certainties and a few surprises.

Study: Remote monitoring of cardiac device patients results in better survival, less hospitalization

Stacy Lawrence / Fierce Medical Devices

Tracking patients who have various cardiac devices via a remote monitoring system cuts down on hospitalizations and costs, while improving patient survival. That's according to a 5-year study by St. Jude Medical ($STJ) of more than 90,000 patients with pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices.

18 May 2015

Marinus Pharmaceuticals Presents Clinical Data of Ganaxolone in Pediatric Epilepsies at Antiepileptic Drug and Device Trials XIII Conference

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, announced that Gail M. Farfel, Ph.D., Chief Clinical and Regulatory Officer of Marinus, presented clinical data on ganaxolone in drug-resistant pediatric epilepsies at the Antiepileptic Drug and Device Trials (AED) XIII conference on Friday, May 15, 2015.

Big Pharma's a C student, rep study finds, with Bayer at the top, Novartis at bottom

Tracy Staton / Fierce Pharma

When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.

Surge in overseas investment drives Israel to life sci fundraising record

Nick Paul Taylor / Fierce Biotech

Israel has joined the list of countries that obliterated their life science fundraising records in 2014. Data from IVC Research Center show Israeli life science companies pulled in $801 million (€708 million) last year, a 55% jump on the previous high that was underpinned by foreign investors opening their checkbooks with unprecedented regularity.

Which global markets should drugmakers target? China, yes--but old European standbys, too

Emily Wasserman / FiercePharma

Big Pharma has some serious ground to cover when it comes to global sales and marketing. Worldwide spending for prescription branded drugs and generic medicines is set to increase 30% from 2013-2018 with $1.3 trillion in annual global drug sales on the line, according to data from the Institute of Healthcare Informatics cited by The Motley Fool blog. And drugmakers should look at markets around the world for their cut of the revenues.